Dr. Reddy’s Files Form 6-K and Publishes July 9 Investor Call Recording
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
Dr Reddy’s Laboratories ( (RDY) ) has issued an announcement.
On July 10, 2026, Dr. Reddy’s Laboratories filed a Form 6-K with the U.S. Securities and Exchange Commission, confirming regulatory compliance as a foreign private issuer. The filing was signed by Company Secretary K Randhir Singh and included a reference to an exhibit related to recent corporate communication.
In a concurrent intimation dated July 10, 2026 to stock exchanges in India and the U.S., the company disclosed the availability of an audio recording of its conference call held on July 9, 2026. By publicly sharing the call recording, Dr. Reddy’s reinforced its disclosure practices and provided investors and other stakeholders with transparent access to its latest management discussion.
The most recent analyst rating on (RDY) stock is a Buy
with a $1540.00 price target.
To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock,
see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Neutral.
The score is driven mainly by solid but weakening fundamentals (margin/ROE compression and higher debt despite growth) and a balanced earnings-call outlook that points to FY27 margin recovery but highlights near-term profitability and working-capital risks. Technicals are neutral-to-soft and valuation support is limited given the P/E and low yield.
To see Spark’s full report on RDY stock,
click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited is a global pharmaceutical company based in Hyderabad, India, focused on developing, manufacturing and marketing generic medicines, active pharmaceutical ingredients and proprietary products. The company is listed on exchanges in India and the U.S., reflecting its international investor base and role as a major player in the generic drug industry.
Its multi-exchange presence, including the National Stock Exchange of India, BSE, the New York Stock Exchange and NSE IFSC, underscores its access to both domestic and global capital markets. This broad listing footprint supports Dr. Reddy’s growth strategy and enhances visibility among institutional and retail investors across geographies.
Average Trading Volume: 2,633,433
Technical Sentiment Signal: Buy
Current Market Cap: $11.81B
See more insights into RDY stock on TipRanks’ Stock Analysis page.
